- Tel: 858.663.9055
-
Email: info@nsjbio.com
- Tel: 858.663.9055
- Email: info@nsjbio.com
MART-1, also known as Melan A or MLANA, is a melanocyte-associated antigen involved in melanosome formation and pigment production and is widely expressed in normal melanocytes and melanocytic tumors. It is recognized as a key antigen associated with melanocytic differentiation and is commonly used as a marker for identifying melanoma and related lesions. In immunohistochemistry, MART-1 is detected as cytoplasmic HRP-DAB brown staining in melanocytes and melanoma cells, providing a clear and reliable pattern for identifying melanocytic lineage in FFPE tissue sections. MART-1 Antibody for IHC is frequently used in studies of melanoma biology and tumor identification.
MART-1 antibody, also referred to as Melan A antibody or MLANA antibody in the literature, recognizes a cytoplasmic protein with highly restricted expression in melanocytic cells. This MART-1 Antibody for IHC is optimized for Tissue Microarray (TMA)-based immunohistochemistry, enabling high-throughput evaluation of melanocyte-associated antigen expression across diverse tissue panels. In normal tissue TMAs, staining is limited to melanocytes, while the majority of non-melanocytic tissues remain negative, reinforcing its specificity for melanocytic lineage detection.
In cancer tissue microarrays, MART-1 expression is strongly associated with melanoma, where diffuse cytoplasmic staining highlights tumor cells with melanocytic origin. This staining pattern enables clear visualization of tumor cell populations within complex tumor microenvironments and supports differentiation from non-melanocytic malignancies. The absence of staining in most epithelial and mesenchymal tumors further supports its lineage specificity.
Tissue Microarray (TMA) analysis allows direct comparison of MART-1 expression across a wide range of normal and cancer tissues under standardized conditions, demonstrating consistent and reproducible staining in melanocytic tumors with minimal background signal. Clone MSVA-900M provides clear and well-defined cytoplasmic staining across TMA cores, supporting its use in melanoma-focused tissue profiling and antigen-based studies. Observed staining patterns are consistent with established MLANA expression profiles and publicly available datasets such as the Human Protein Atlas.
This antibody targets MART-1 in research applications requiring reliable immunohistochemical detection of melanoma-associated antigens, making it well suited for studies of melanoma biology, tumor identification, and melanocytic differentiation.
This antibody is part of the Melan-A antibody collection, where additional MLANA/MART-1 antibodies for various applications can be explored.
This antibody is also part of a broader collection of IHC antibodies validated by tissue microarray analysis, supporting consistent staining across normal and cancer tissues.
1. Optimal dilution of the MART-1 Antibody for IHC / Melanoma Antigen Immunohistochemistry Antibody should be determined by the researcher.
2. This MART-1/Melanoma antigen recognized by T-cells 1 antibody is recombinantly produced by expression in human HEK293 cells.
3. Manual Protocol: Freshly cut sections should be used (less than 10 days between cutting and staining). Heat-induced antigen retrieval for 5 minutes in an autoclave at 121oC in pH 7.8 Target Retrieval Solution buffer. Apply the antibody at a dilution of 1:150 at 37oC for 60 minutes. Visualization of bound antibody by the EnVision Kit (Dako, Agilent) according to the manufacturer's directions.
Recombinant full-length hMART-1 protein was used as the immunogen for the MART-1/Melanoma antigen recognized by T-cells 1 antibody.
MART-1/Melanoma antigen recognized by T-cells 1 antibody with sodium azide - store at 2 to 8oC; antibody without sodium azide - store at -20 to -80oC.
MART-1 antibody, MLANA antibody, Melan-A antibody, melanoma antigen recognized by T cells antibody, melanocyte marker antibody
Your bulk quote request has been submitted successfully!
Please contact us if you have any questions.